O	0	3	The
O	4	8	GISS
O	9	14	trial
O	14	15	:
O	16	17	a
O	18	23	phase
O	24	26	II
O	27	37	prevention
O	38	43	trial
O	44	46	of
B-intervention	47	56	screening
I-intervention	57	61	plus
I-intervention	62	71	goserelin
I-intervention	71	72	,
I-intervention	73	84	ibandronate
O	84	85	,
O	86	92	versus
B-control	93	102	screening
I-control	103	108	alone
O	109	111	in
O	112	125	premenopausal
O	126	131	women
O	132	134	at
O	135	144	increased
O	145	149	risk
O	150	152	of
O	153	159	breast
O	160	166	cancer
O	166	167	.

O	168	175	Genetic
O	176	183	testing
O	184	187	for
O	188	197	inherited
O	198	207	mutations
O	208	210	in
O	211	217	breast
O	218	224	cancer
O	225	230	genes
O	231	239	provides
O	240	248	valuable
O	249	260	information
O	261	264	for
O	265	272	disease
O	273	283	prevention
O	283	284	.

O	285	290	Today
O	290	291	,
B-eligibility	292	305	premenopausal
I-eligibility	306	311	women
I-eligibility	312	316	with
I-eligibility	317	326	increased
I-eligibility	327	331	risk
I-eligibility	332	335	for
I-eligibility	336	342	breast
I-eligibility	343	349	cancer
O	350	354	have
O	355	359	only
O	360	367	limited
O	368	379	nonsurgical
O	380	387	options
O	388	390	to
O	391	397	reduce
O	398	403	their
O	404	408	risk
O	408	409	.

O	410	413	The
O	414	418	GISS
O	419	424	trial
O	424	425	,
O	426	427	a
O	428	438	randomized
O	438	439	,
O	440	451	multicenter
O	451	452	,
O	453	457	open
O	457	458	-
O	458	463	label
O	464	469	phase
O	470	472	II
O	473	478	trial
O	478	479	,
O	480	488	assessed
O	489	492	the
O	493	504	feasibility
O	505	507	of
O	508	509	a
O	510	520	preventive
O	521	530	treatment
O	531	535	with
O	536	545	goserelin
O	546	549	and
O	550	561	ibandronate
O	562	565	for
O	566	579	premenopausal
O	580	585	women
O	586	588	at
O	589	598	increased
O	599	603	risk
O	604	607	for
O	608	614	breast
O	615	621	cancer
O	621	622	.

O	623	626	The
O	627	634	primary
O	635	644	endpoints
O	645	649	were
B-outcome-Measure	650	657	refusal
I-outcome-Measure	658	660	to
I-outcome-Measure	661	668	undergo
I-outcome-Measure	669	682	randomization
O	683	686	and
B-outcome-Measure	687	702	discontinuation
I-outcome-Measure	703	705	of
I-outcome-Measure	706	715	treatment
O	715	716	.

B-outcome-Measure	717	723	Safety
I-outcome-Measure	724	727	and
I-outcome-Measure	728	735	quality
I-outcome-Measure	736	738	of
I-outcome-Measure	739	743	life
O	744	748	were
O	749	753	also
O	754	763	evaluated
O	763	764	.

O	765	772	Between
O	773	776	the
O	777	782	years
O	783	787	2001
O	788	791	and
O	792	796	2003
O	796	797	,
B-total-participants	798	800	31
O	801	803	of
O	804	807	322
O	808	816	eligible
O	817	822	women
O	823	835	participated
O	836	838	in
O	839	842	the
O	843	848	trial
O	848	849	;
B-intervention-participants	850	852	15
O	853	861	received
O	862	871	goserelin
O	871	872	/
O	872	883	ibandronate
O	884	888	plus
O	889	898	screening
O	898	899	,
B-control-participants	900	902	15
O	903	912	screening
O	913	917	only
O	917	918	,
O	919	922	and
O	923	924	1
O	925	933	withdrew
O	934	937	her
O	938	945	consent
O	946	951	after
O	952	965	randomization
O	965	966	.

O	967	970	The
O	971	980	treatment
O	981	989	duration
O	990	993	was
O	994	996	24
O	997	1003	months
O	1003	1004	.

O	1005	1009	Here
O	1009	1010	,
O	1011	1017	mainly
O	1018	1021	the
O	1022	1029	results
O	1030	1034	from
O	1035	1038	the
O	1039	1044	first
O	1045	1047	12
O	1048	1054	months
O	1055	1059	were
O	1060	1069	evaluated
O	1070	1077	because
O	1078	1080	of
O	1081	1084	the
O	1085	1088	low
O	1089	1099	compliance
O	1100	1110	thereafter
O	1110	1111	.

B-outcome	1112	1115	Hot
I-outcome	1116	1123	flushes
O	1123	1124	,
B-outcome	1125	1133	headache
O	1133	1134	,
O	1135	1138	and
B-outcome	1139	1146	vaginal
I-outcome	1147	1154	dryness
I-outcome	1154	1155	/
I-outcome	1155	1164	discharge
O	1165	1173	occurred
O	1174	1178	more
O	1179	1184	often
O	1185	1187	in
O	1188	1191	the
O	1192	1201	goserelin
O	1202	1205	arm
O	1205	1206	.

O	1207	1209	No
O	1210	1220	difference
O	1221	1224	was
O	1225	1233	observed
O	1234	1241	between
O	1242	1245	the
O	1246	1249	two
O	1250	1254	arms
O	1255	1257	in
O	1258	1261	the
B-outcome	1262	1271	agreement
I-outcome	1272	1274	to
I-outcome	1275	1288	randomization
O	1288	1289	,
O	1290	1300	compliance
O	1300	1301	,
O	1302	1304	or
O	1305	1308	any
O	1309	1314	other
O	1315	1324	endpoints
O	1324	1325	.

B-outcome	1326	1336	Acceptance
I-outcome	1337	1339	of
I-outcome	1340	1355	chemoprevention
O	1356	1360	with
O	1361	1370	goserelin
O	1371	1374	and
O	1375	1386	ibandronate
O	1387	1390	was
O	1391	1394	low
O	1394	1395	.

O	1396	1409	Premenopausal
O	1410	1415	women
O	1416	1418	at
O	1419	1428	increased
O	1429	1433	risk
O	1434	1437	for
O	1438	1444	breast
O	1445	1451	cancer
O	1452	1458	should
O	1459	1461	be
O	1462	1468	better
O	1469	1477	informed
O	1478	1483	about
O	1484	1499	chemoprevention
O	1500	1507	through
O	1508	1517	physician
O	1518	1528	counseling
O	1529	1532	and
O	1533	1534	a
O	1535	1539	more
O	1540	1548	feasible
O	1549	1554	study
O	1555	1561	design
O	1562	1563	(
O	1563	1564	e
O	1564	1565	.
O	1565	1566	g
O	1566	1567	.
O	1567	1568	,
O	1569	1573	oral
O	1574	1584	medication
O	1584	1585	)
O	1586	1592	should
O	1593	1595	be
O	1596	1604	provided
O	1604	1605	.

O	1606	1610	This
O	1611	1613	is
O	1614	1617	the
O	1618	1623	first
O	1624	1639	chemoprevention
O	1640	1645	trial
O	1646	1648	in
O	1649	1662	premenopausal
O	1663	1668	women
O	1669	1671	at
O	1672	1681	increased
O	1682	1686	risk
O	1687	1690	for
O	1691	1697	breast
O	1698	1704	cancer
O	1704	1705	.
